The Coalition for Epidemic Preparedness Innovations (CEPI) and Intravacc today announced the latest funding award to advance the development of vaccines that provide broad protection against SARS-CoV-2 (including its variants) and other Betacoronaviruses, which can be delivered intranasally.
Based in the Netherlands, the CEPI will provide seed funding of up to US$4.8 million to Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines.
Read More
